SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension
ConditionAtrial Hypertension
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age60+
SponsorProf. Dr. med. Ingo Eitel
About this trial
Hypertension (HTN) is a leading cause of cardiovascular disease (CVD). Despite existing therapies, patients with HTN still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (BP) control. SGLT2 inhibitors (SGLT2i) are recommended for both type-2 diabetes and heart failure to reduce morbidity and mortality. SGLT2i reduce BP and might also improve outcomes for HTN by reducing end-organ damage through diverse other actions. However, confirmation that SGLT2i are clinically useful for the management of HTN is required to change guidelines and clinical practice.
Eligibility criteria
Qualifiers
Age ≥60 years
Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg in two measurements on different days for newly diagnosed hypertension, or through one measurement at the screening visit for patients with an existing diagnosis of hypertension.
A history of at least one CV event (myocardial infarction* or stroke*; stable angina or clinical evidence of coronary heart disease; peripheral arterial disease; transient ischemic attack)
Disqualifiers
Known secondary cause of hypertension
Myocardial infarction or stroke within the previous 3 months
Symptomatic heart failure (including HFrEF, HFmEF, HFpEF)
History of Diabetes mellitus
Trial design
Treatments tested in this trial
- SGLT2
- Placebo
Treatment groups
3,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
Prof. Dr. med. Ingo Eitel
Lead sponsor
University of Luebeck
Sponsor institution
Source ClinicalTrials.gov